2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.19. IDH1 and IDH2 Mutations in Non-small Cell Lung Cancer (NSCLC)

Pdf Summary

This study focused on the mutations in IDH1 and IDH2 genes in non-small cell lung cancer (NSCLC). Mutations in these genes can lead to epigenetic dysregulation and contribute to the development of cancer. The researchers analyzed a large cohort of NSCLC samples and found that IDH1 mutations were present in 0.5% of the tumors, while IDH2 mutations were less common with an incidence of 0.1%.<br /><br />The study also investigated the mutational landscape and found that IDH1 and IDH2 mutations often occurred in conjunction with other potential driver alterations such as KRAS, NTRK3 fusions, and BRAF. The presence of these mutations was associated with a distinct tumor immune microenvironment. NSCLC tumors with IDH1 mutations had decreased B-cell infiltration and increased myeloid dendritic cell infiltration, as well as increased expression of certain immune-related markers. Similarly, NSCLC tumors with IDH2 mutations had increased myeloid dendritic cell and macrophage infiltration and increased expression of immune-related markers. PD-L1 expression, a biomarker for immunotherapy response, was noted in a significant portion of tumors with IDH1 mutations.<br /><br />The results suggest that IDH1 and IDH2 mutations are not primary drivers of NSCLC but may play a role in mediating acquired or intrinsic resistance to treatment. The study highlights the importance of further investigation into combination strategies targeting these mutations. The researchers used next-generation sequencing techniques to analyze the genetic and transcriptomic characteristics of the NSCLC samples.<br /><br />In conclusion, this study provides insights into the prevalence and mutational landscape of IDH1 and IDH2 mutations in NSCLC. The findings suggest that these mutations may have implications for immune response and treatment resistance in NSCLC patients. Further research is needed to understand the specific mechanisms and potential therapeutic strategies associated with IDH1 and IDH2 mutations in NSCLC.

Asset Subtitle

Lacey Williams, Georgetown University, United States

Meta Tag

Speaker Lacey Williams, Georgetown University, United States

Topic Poster Listing

Keywords

mutations

IDH1

IDH2

NSCLC

mutational landscape

tumor immune microenvironment

immunotherapy response

acquired resistance

combination strategies

next-generation sequencing